Back to results
US 2025/0102510 A1Published application
Lectin-based diagnostics of cancers
AssigneeUniogen Oy
InventorsKamlesh GIDWANI, Kim PETTERSSON, Henna KEKKI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to non-invasive diagnostics of cancers, especially breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers.
Claims13
A method for treating breast cancer in a subject in need thereof, said method comprising:
- (a) assaying a sample obtained from said subject to detect a level of carbohydrate antigen 15-3 (CA15-3) glycoform that binds to at least one of macrophage galactose-type lectin (MGL) or wheat germ agglutin (WGA), wherein:
- (i) the CA15-3 glycoform is CA15-3MGL, and wherein a CA15-3 specific antibody is used as a capturing agent and MGL is used as a detectably labelled tracer, or wherein MGL is used as a capturing agent and a CA15-3 specific antibody is used as a detectably labelled tracer, or
- (ii) the CA15-3 glycoform is CA15-3WGA, wherein a CA15-3 specific antibody is used as a capturing agent and WGA is used as a detectably labelled tracer, or wherein WGA is used as a capturing agent and a CA15-3 specific antibody is used as a detectably labelled tracer;
- (b) comparing the detected level of said at least one of CA15-3MGL or CA15-3WGA in said sample with a detected level of said at least one of CA15-3MGL or CA15-3WGA in a healthy control sample, a benign control sample, or a predetermined threshold value;
- and
- (c) when the detected level of said at least one of CA15-3MGL or CA15-3WGA in said sample is increased compared to the detected level of said at least one of CA15-3MGL or CA15-3WGA in said healthy control sample, said benign control sample, or said predetermined threshold value, treating said subject for said breast cancer with surgery, radiation therapy, chemotherapy, or any combination thereof.
3 more elements
Dependencies are inferred from the claim text.